Posted by Michael Wonder on 29 Nov 2022
Capstone announces authorisation of biosimilar human insulin for IV infusion in Canada and EU
29 November 2022 - Capstone announced today that a biosimilar version of human insulin received authorisation from the EMA's CHMP and a Notice of Compliance from Health Canada. The product is the only ready to use insulin for intravenous infusion.
It received approval from the US FDA in 2019.
